<DOC>
	<DOCNO>NCT01871675</DOCNO>
	<brief_summary>The goal study characterize safety , maximum tolerate dose ( MTD ) preliminary efficacy profile IPI-145 give combination rituximab , bendamustine plus rituximab , subject select relapsed/refractory hematologic malignancy .</brief_summary>
	<brief_title>Study IPI-145 Combination With Rituximab Bendamustine/Rituximab Hematologic Malignancies</brief_title>
	<detailed_description>This trial consist two parallel arm . For treatment arm , 3+3 dose escalation design apply 3-6 subject cohort maximum tolerate dose IPI-145 give rituximab ( Arm 1 ) combination rituximab bendamustine ( Arm 2 ) determine . Treatment arm selection choose investigator depend agent previously administer subject . Once MTD determine , arm move dose expansion phase . During dose expansion phase , treatment arm enroll population specific cohort assess efficacy . All subject must least one prior anticancer treatment . The dose expansion cohort : Arm 1 : Cohort A - CLL : Cohort B - CD20+ NHL Arm 2 : Cohort A - CLL : Cohort B - CD20+ NHL</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Lymphoma , T-Cell</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Bendamustine Hydrochloride</mesh_term>
	<criteria>1 . Dose Escalation Phase Arm 1 Arm 2 : Limited subject diagnose low grade CD20 positive BCell NHL least one prior anticancer treatment . 2 . Dose Expansion Phase Arm 1 Cohort A : Limited subject CD20 positive CLL least one prior anticancer treatment . Arm 1 Cohort B : Limited subject diagnosis CD20 positive NHL least one prior anticancer treatment . Arm 2 Cohort A : Limited subject CD20 positive CLL least one prior anticancer treatment . Arm 2 Cohort B : Limited subject diagnosis CD20 positive NHL least one prior anticancer treatment . 3 . Disease status requirement : CLL subject : symptomatic disease mandate treatment ; Indolent NHL subject : symptomatic disease require treatment accord clinical judgment investigator ; Other lymphoma subject : disease require treatment accord judgment investigator . 4 . Eastern Cooperative Oncology Group ( ECOG ) Performance Status score ≤2 . 5 . Subject must measurable disease use diseasespecific response criterion NHL CLL 6 . Age ≥ 18 year . 7 . Subject recover clinically significant toxicity relate prior antineoplastic therapy exception alopecia bone marrow organ function . 8 . Adequate organ system function ≤2 week prior Day 1 , define follow : Absolute neutrophil count ( ANC ) ≥1.0 x 109/L unless relate underlying CLL indolent NHL bone marrow involvement , ANC ≥500 x 109/L permit . Platelets ≥100 x 109/L unless relate underlying CLL indolent NHL bone marrow involvement , platelet ≥75 x 109/L permit . Subjects receive IPI145 plus rituximab bone marrow involvement may enroll platelet ≥40 x 109/L . Alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) ≤1.5 x ULN total bilirubin ≤1.5 time upper limit normal ( ULN ) ( except subject Gilbert 's disease ) Serum creatinine ≤1.5 x ULN 9 . Life expectancy ≥12 week . 10 . Women childbearing potential ( WCBP ) must negative serum urine pregnancy test . 11 . Ability understand nature study give write informed consent . 1 . Prior allogeneic hematopoietic stem cell transplant ( HSCT ) . 2 . Prior autologous transplant radioimmunotherapy ≤6 month prior first dose trial treatment . 3 . Subject high grade lymphoma Burkitt 's , lymphoblastic small noncleaved cell lymphoma . Subjects intermediate grade lymphoma ( diffuse large Bcell lymphoma ) eligible . 4 . Subjects diffuse Bcell lymphoma must either eligible autologous bone marrow transplant ( BMT ) relapse autologous BMT . 5 . More three previous cytotoxic chemotherapy regimens subject treat arm containing bendamustine . 6 . Subjects severe allergic anaphylactic reaction humanize murine monoclonal antibody . 7 . Chemotherapy , cancer immunosuppressive therapy , growth factor ( except erythropoietin ) , radiation therapy ( whole brain irradiation [ WBI ] ) surgery ablative therapy investigational drugs/devices ≤28 day first dose trial treatment . 8 . Subjects receive high dos corticosteroid must taper stable dose least 7 day first dose trial treatment . 9 . Tyrosine kinase inhibitor within 7 day prior first dose trial treatment . 10 . Subjects overt leptomeningeal leukemia central nervous system ( CNS ) lymphoma . Subjects must free CNS disease minimum 2 month . Subjects symptoms CNS disease must negative diagnostic lumbar puncture prior study enrollment . 11 . Subjects history stroke , unstable angina , myocardial infarction , ventricular arrhythmia require medication mechanical control within last 6 month . 12 . Baseline QTcF &gt; 480 m . Note : This criterion apply subject leave bundle branch block . 13 . Subjects venous thromboembolic event require anticoagulation meet follow criterion : Have stable dose anticoagulation &lt; 1 month . Have Grade 2 , 3 4 hemorrhage last 30 day . Are experience continue symptom venous thromboembolic event . 14 . Subjects history liver disease result alcohol abuse , chronic hepatitis , chronic liver disease ( metastatic disease liver ) . 15 . Subjects positive HBsAg , HBcAb HCV exclude . 16 . Subjects history tuberculosis within precede two year . 17 . Prior surgery affect drug absorption gastrointestinal dysfunction could alter drug absorption . 18 . Subjects know hypersensitivity bendamustine rituximab . 19 . Presence active infection within 72 hour treatment . Subjects ongoing use prophylactic antibiotic eligible long evidence active infection antibiotic include list prohibit medication . 20 . Known diagnosis human immunodeficiency virus ( HIV ) . 21 . Concurrent administration medication food strong moderate inhibitor inducer CYP3A . 22 . Women pregnant lactating . 23 . Psychological , familial , sociological , geographical condition permit compliance protocol . 24 . Concurrent condition investigator 's opinion would jeopardize compliance protocol would impart excessive risk associate study participation would make inappropriate subject enrol . 25 . Inability unwillingness comply study and/or followup procedure outline protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Lymphoma</keyword>
	<keyword>Chronic Lymphocytic Leukemia</keyword>
	<keyword>Non-Hodgkin Lymphoma</keyword>
	<keyword>T-cell Lymphoma</keyword>
	<keyword>Rituxan</keyword>
	<keyword>Bendamustine</keyword>
	<keyword>Hematologic Malignancy</keyword>
	<keyword>Relapsed</keyword>
	<keyword>Refractory</keyword>
</DOC>